In this episode, we explore the persistent challenge of subconjunctival fibrosis and scarring in glaucoma filtration surgery, which remains the leading cause of surgical failure despite the standard use of antimetabolites like Mitomycin C (MMC) and 5-fluorouracil (5-FU). We examine the evolution of surgical interventions, from traditional trabeculectomy to modern minimally invasive glaucoma surgery (MIGS) devices such as the PreserFlo MicroShunt and Xen Gel Stent, designed to improve safety profiles while effectively lowering intraocular pressure. The discussion highlights innovative therapeutic agents currently under investigation to modulate wound healing, including the antioxidant 3',4'-dihydroxyflavonol (DiOHF), anti-VEGF agents like Conbercept, and biodegradable collagen matrices such as Ologen. Furthermore, we look at future frontiers in glaucoma management, including the use of artificial intelligence to identify genetic targets, gene therapy, and sustained-release drug delivery systems.

In this episode, we explore Multicystic Dysplastic Kidney (MCDK), a common congenital anomaly where a non-functioning kidney is replaced by non-communicating cysts due to disrupted nephrogenesis. We discuss the clinical shift from prophylactic nephrectomy to conservative 'watch and wait' management, driven by evidence that the majority of these kidneys spontaneously involute and carry a negligible risk of malignancy, such as Wilms' tumour. Finally, we examine the critical importance of long-term surveillance for the remaining solitary functioning kidney, focusing on the potential for hyperfiltration injury, hypertension, and associated genetic drivers like HNF1B mutations.

In this episode, we unpack the major updates in the 2025 EASL Clinical Practice Guidelines for Autoimmune Hepatitis (AIH), including the removal of AIH subclassification recommendations and the introduction of Mycophenolate Mofetil (MMF) as a viable first-line alternative to azathioprine. We examine the rising global prevalence of AIH, particularly among older adults and minority populations in the United States, and discuss why patients with anti-SLA/LP antibodies may require lifelong immunosuppression. Additionally, we explore a new machine learning model for predicting hepatocellular carcinoma risk in Hepatitis B patients and break down how the MELD score utilizes lab values to prioritize liver transplant candidates.

In this episode, we examine 16p11.2 deletion and duplication syndromes, exploring how a specific chromosomal change creates "mirror" physical effects: deletions are linked to obesity and larger head size, while duplications are associated with low BMI and smaller head size. We discuss core neurological impacts, including speech apraxia, autism, and seizure susceptibility, as well as the distinct psychiatric risks for schizophrenia seen in duplication carriers. Finally, we highlight the 2023 Health Supervision Guidelines, which provide a roadmap for monitoring development, nutrition, and mental health from infancy to adulthood.

In this episode, we navigate the complex landscape of Congenitally Uncorrected (d-TGA) and Corrected Transposition of the Great Arteries (ccTGA), distinguishing between the neonatal emergency of d-TGA's "parallel circulation" and the rare "double discordance" of ccTGA, where the heart is physiologically functional but relies on the weaker right ventricle to pump blood to the body. We discuss the evolution of life-saving surgical interventions, from the standard Arterial Switch Operation for d-TGA to complex procedures like the "Double Switch" and "1.5 Ventricle" repairs designed to prevent ventricular failure. Finally, we examine the critical long-term challenges facing these patients into adulthood, including the management of heart failure, arrhythmias, and tricuspid valve regurgitation.

In this episode, we explore the lifecycle of Esophageal Atresia (EA) management, moving from the molecular impact of the Sonic Hedgehog signaling pathway on foregut development to modern surgical innovations like thoracoscopic repair and the Foker process for long-gap cases. We also examine the critical shift toward lifelong multidisciplinary surveillance, highlighting the substantial risks of Barrett’s esophagus and Eosinophilic Esophagitis (EoE) in adolescent and adult survivors.

In this episode, we explore the aggressive pathology of neovascular glaucoma (NVG), a sight-threatening secondary glaucoma driven by retinal ischaemia and the overexpression of vascular endothelial growth factor (VEGF). We discuss the critical "two-pronged" treatment approach: managing the underlying ischaemic drive through panretinal photocoagulation (PRP) and anti-VEGF injections, while simultaneously controlling intraocular pressure. We examine the comparative outcomes of surgical interventions, specifically the trade-offs between the Ahmed and Baerveldt glaucoma drainage devices, and evaluate the safety profile of micropulse versus continuous wave transscleral cyclophotocoagulation. Finally, we highlight emerging strategies like the SCOPING protocol, designed to salvage the conventional outflow pathway in eyes with open or partially open angles.

In this episode, we examine hypoparathyroidism, a rare endocrine deficiency predominantly caused by anterior neck surgery, though also arising from autoimmune disorders, genetic defects, or infiltrative conditions such as Wilson's disease and iron overload in thalassaemia. We discuss the substantial clinical burden, characterised by complications including nephrocalcinosis, basal ganglia calcifications, cataracts, and significantly impaired quality of life under conventional calcium and active vitamin D management. Finally, we cover ground-breaking therapeutic shifts, including the recent FDA approval of palopegteriparatide (Yorvipath), a long-acting prodrug which restores physiological PTH levels and improves renal function, alongside emerging research into oral PTH tablets and parathyroid transplantation techniques.

In this episode, we explore the evolving clinical landscape of cholestatic liver diseases, highlighting the 2025 therapeutic revolution in Primary Biliary Cholangitis (PBC) marked by the market withdrawal of obeticholic acid and the accelerated approval of novel PPAR agonists like seladelpar and elafibranor. We contrast this with Primary Sclerosing Cholangitis (PSC), where management remains focused on surveillance via MRI/MRCP and endoscopic intervention for strictures rather than disease-modifying pharmacotherapy. Finally, we discuss essential risk stratification tools like the GLOBE score and liver stiffness measurement, alongside emerging treatments for debilitating cholestatic pruritus, including the investigative IBAT inhibitors volixibat and linerixibat.

In this episode, we explore the complex landscape of Immune Thrombocytopenia (ITP), an autoimmune disorder characterized by platelet destruction and impaired production. We discuss the critical diagnostic challenge of distinguishing ITP from genetic mimics, particularly MYH9-related disease, which is often misdiagnosed as ITP but can be identified by giant platelets and Döhle-like bodies in neutrophils.

We also examine the evolving therapeutic paradigm for 2025, highlighting the shift from broad immunosuppression toward targeted therapies like the specific Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib and the neonatal Fc receptor (FcRn) antagonist efgartigimod. Additionally, we review promising Phase 3 results for ianalumab, a novel agent targeting the BAFF receptor, which may offer disease-modifying potential. Finally, we address the burden of fatigue and health-related quality of life, emphasizing that while pediatric cases often resolve spontaneously, adult ITP frequently requires long-term management to mitigate bleeding risks and treatment side effects.